📄 What This Document Is

This is the transcript of an investor conference call held on March 31, 2026. Biogen (BIIB) executives are explaining their proposed acquisition of Apellis Pharmaceuticals (APLS). Think of it as a live Q&A session where Biogen's leadership justifies the deal to Wall Street analysts, explaining their strategy, the financials, and how the two companies fit together.

👉 In simple terms: Biogen is buying Apellis to get two new, on-the-market drugs and a ready-made team in a new disease area (kidney disease).

🏢 What The Companies Do

Biogen (BIIB): A giant biotech historically focused on neuroscience (e.g., multiple sclerosis, Alzheimer's). Over the last few years, it has expanded its focus to include immunology and rare diseases. They have a strong pipeline of drugs in development, but their growth drivers mostly start around 2028.

Apellis Pharmaceuticals (APLS): A biotech focused on complement inhibitors (drugs that target part of the immune system). It has two main products already on the market:

• SYFOVRE: The first FDA-approved treatment for geographic atrophy (GA), a serious, irreversible form of age-related macular degeneration that leads to vision loss.
• EMPAVELI: Approved for PNH (a rare blood disorder) and, more recently, for two rare immune-mediated kidney diseases (C3G and IC-MPGN).

👉 Why it matters: Biogen is trading its pure neuroscience focus for a broader platform. Apellis gives them immediate commercial products and expertise in eye and kidney diseases, which aligns with Biogen's new strategy.

💰 The Deal & Financial Highlights

The deal is an all-cash offer from Biogen to buy all of Apellis.

• Price: $41 per share.
• Total Upfront Value: Approximately $5.6 billion. This includes cash plus "contingent value rights" (CVRs)—extra payments to Apellis shareholders if SYFOVRE hits certain future sales milestones.
• Financing: Biogen is using cash on hand, drawing from a revolving credit line, and taking a new bank loan.
• Expected Close: Second quarter of 2026.
• Financial Impact: The deal is expected to boost Biogen's earnings (non-GAAP EPS) starting in 2027 and significantly increase their earnings growth rate through 2030. They plan to pay off all the debt taken for the acquisition by the end of 2027.

👉 Why it matters: Biogen is making a big, expensive bet but says it won't overstretch its finances. They believe the growth from Apellis's drugs will quickly justify the cost.

🚀 The Strategic Rationale: Why Buy Apellis?

Biogen's CEO, Chris Viehbacher, outlined four key criteria for an acquisition, and believes Apellis meets them all:

1. No Big Pipeline Risk: Apellis's drugs are already approved and launching. Biogen's own pipeline is full, so they didn't want to take on more late-stage drug development risk.
2. Strategic Fit: It expands Biogen into immunology and rare diseases—areas they are already committed to.
3. Manageable Debt: The $5.6B price tag fits within their comfort zone of up to $5-6 billion and doesn't strain their balance sheet.
4. Value-Creating Price: They believe the $41/share price is fair and will still create value for Biogen shareholders based on their own revenue forecasts.

The Big Synergy: The acquisition gives Biogen an instant, experienced commercial team in nephrology (kidney disease). This is critical because Biogen has its own promising kidney drug, felzartamab, in development. Instead of building a sales force from scratch, they can use Apellis's existing team and relationships to launch felzartamab faster and more effectively.

📦 The Products: Growth Engines

SYFOVRE (for Geographic Atrophy):

• Opportunity: A huge market with ~1.5 million diagnosed patients in the U.S., but less than 10% are currently treated.
• Challenges: Competition is fierce. A key hurdle is that patients don't see an immediate benefit (the drug slows progression, not restores vision), leading to high dropout rates. Also, there's a competitor drug from Astellas.
• Biogen's Plan: Use their expertise in patient education and support (learned from rare disease launches) to improve patient activation and persistence. A prefilled syringe version is coming, which doctors prefer, to gain a competitive edge.

EMPAVELI (for Rare Kidney Diseases):

• Opportunity: Early in its launch for C3G and IC-MPGN. It's the only FDA-approved therapy for these conditions. Biogen sees this as an "underappreciated" asset with significant growth potential.
• Key Advantage: It gives Biogen an immediate presence in nephrology. There's a ~50% overlap between the doctors who prescribe EMPAVELI and those who would prescribe Biogen's future drug, felzartamab.

🔮 What's Next & Guidance

• Near-Term: Focus on integrating Apellis and continuing the launches of SYFOVRE and EMPAVELI. They expect combined revenue growth for these two products in the mid to high teens for the next couple of years.
• 2027: The deal becomes meaningfully accretive (adds to earnings per share). Biogen aims to have paid down all acquisition debt by year-end.
• Long-Term: The acquisition is a cornerstone for growth this decade. It provides a foundation for launching felzartamab and building a broader kidney disease franchise. Biogen says it will now focus on early-stage assets and is not planning another large acquisition soon.
• Updated Guidance: Biogen will update its full-year 2026 financial forecast when it reports Q1 earnings.

⚖️ The Big Picture: Strengths & Risks

👍 Strengths / Bull Case:

• Strategic Fit: Perfectly matches Biogen's new focus on immunology and rare diseases.
• Immediate Cash Flow: Adds two marketed products, filling a near-term growth gap before Biogen's own pipeline kicks in.
• Commercial Synergy: Biogen's launch expertise + Apellis's nephrology team = a powerful combo for future growth (especially for felzartamab).
• Conservative Financing: Debt is manageable and will be paid down relatively quickly.

⚠️ Risks / Bear Case:

• SYFOVRE Execution: The GA market is competitive and tough to penetrate. Success hinges on improving patient persistence and overcoming the "no immediate benefit" perception.
• Long-Term Forecast Uncertainty: Biogen's executives admit there's a wide range of possible outcomes, especially for the long-term sales of the kidney drugs, due to uncertain epidemiology (how many patients exist and can be identified).
• Premium Paid: Biogen is paying a significant premium over Apellis's recent stock price. Their defense is that the stock price was depressed by market pressure, not the drug's long-term potential.

🧠 The Analogy

Think of Biogen as a top-tier restaurant renowned for its complex, experimental tasting menu (its neuroscience pipeline). It's famous, but the dishes take years to develop. To ensure steady revenue while chefs work in the back, the owner buys a popular, established food truck (Apellis) with two best-selling items already on the menu (SYFOVRE and EMPAVELI). The food truck also comes with a fantastic grill master (the nephrology team) who can help the restaurant launch its next big steak dish (felzartamab) much faster.

📇 Key Contacts & People

• Timothy Power: Head-Investor Relations, Biogen
• Christopher A. Viehbacher: President, Chief Executive Officer & Director, Biogen
• Adam Keeney: Executive Vice President & Head-Corporate Development, Biogen
• Robin C. Kramer: Executive Vice President & Chief Financial Officer, Biogen
• Alisha A. Alaimo: President, Head-North America & Board Member-Biogen Foundation, Biogen
• Priya Singhal: Executive Vice President & Head-Development, Biogen

🧩 Final Takeaway

Biogen is using its financial strength to solve a strategic gap: near-term growth. By buying Apellis, it gets two growth products today and, more importantly, buys the commercial launchpad it needs to maximize the potential of its own promising kidney drug, felzartamab, in the future. The success of this expensive bet depends on executing in two very different, competitive disease markets.